Discover 1,123 paid clinical trials in Alabama. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Alabama provides a diverse range of research opportunities for healthy volunteers and individuals with specific health conditions. Leading research centers in Birmingham, Montgomery, and Mobile are seeking participants, offering access to innovative treatments and cutting-edge medical care.
Filter
1
Filter results
Results: 1,123
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
for
Acute Myeloid Leukemia
Location: Halifax, Bangor ME, Scarborough ME, Boston MA,
Sponsor: Children's Oncology Group
Sex: All
Age: 0 - 21
Code: NCT04293562
Phase 3, Recruiting
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
for
Locoregional Recurrence,
Location: Boston MA, New York NY, New Brunswick NJ, Hershey PA,
Sponsor: Oana Danciu
Sex: All
Age: 18+
Code: NCT05467891
Phase 2, Recruiting
Combination Therapy for the Treatment of Diffuse Midline Gliomas
for
Diffuse Intrinsic Pontine Glioma,
Location: Boston MA, New York NY, Hackensack NJ, Philadelphia PA,
Sponsor: University of California, San Francisco
Sex: All
Age: 2 - 39
Code: NCT05009992
Phase 2, Recruiting
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging
Evaluate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.
for
Hidradenitis Suppurativa
Location: Birmingham AL
Sponsor: University of Alabama at Birmingham
Sex: All
Age: 18+
Code: NCT06326476
Early Phase 1, Recruiting
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
for
Heart Failure
Location: St. John's, Sydney, Halifax, Moncton, Saint John,
Sponsor: AstraZeneca
Sex: All
Age: 40+
Code: NCT06677060
Phase 3, Recruiting
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
for
Extensive-Stage Small Cell Lung Cancer
Location: Durham NC, Roanoke VA, Orange City FL, Fort Myers FL,
Sponsor: Bristol-Myers Squibb
Sex: All
Age: 18+
Code: NCT06646276
Phase 3, Recruiting
Product Surveillance Registry
for
Cardiac Rhythm Disorders, Urological Disorders,
Location: Boston MA, Riverhead NY, Hartford CT, Holyoke MA,
Sponsor: Medtronic
Sex: All
Age: 0+
Code: NCT01524276
Recruiting
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
for
Malignant Female Reproductive System Neoplasm,
Location: Brewer ME, Augusta ME, Scarborough ME, Providence RI,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06126276
Phase 2, Recruiting
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
for
Acute Leukemia of Ambiguous Lineage,
Location: Scarborough ME, Boston MA, Providence RI, Worcester MA,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 0 - 1
Code: NCT06317662
Phase 2, Recruiting
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
for
Cystic Fibrosis
Location: Boston MA, Worcester MA, New Hyde Park NY, Valhalla NY,
Sponsor: Nicole Hamblett
Sex: All
Age: 12+
Code: NCT06504589
Recruiting
DALY II USA/ MB-CART2019.1 for DLBCL
for
Refractory Diffuse Large B Cell Lymphoma (DLBCL),
Location: Boston MA, New Haven CT, New York NY, Baltimore MD,
Sponsor: Miltenyi Biomedicine GmbH
Sex: All
Age: 18+
Code: NCT04792489
Phase 2, Recruiting
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors